Novo Nordisk’s Wegovy pill, a new oral treatment for obesity, has seen rapid uptake since its January launch, with over 600,000 prescriptions written within three months. This oral option is attracting a demographic previously deterred by the high costs and needle-based delivery of GLP-1 injections, suggesting a significant expansion of the obesity treatment market. Analysts at BMO Capital Markets noted the pill’s appealing price point of $149 per month as a key factor driving demand, especially among patients who have struggled to access injectable alternatives.
Despite the promising start, Novo’s stock has not reflected this initial success, as the company faces competition from Eli Lilly’s newly approved GLP-1 pill, Foundayo. While Wegovy is expected to contribute significantly to revenue growth—projected to increase from $13.5 billion in 2026 to $18.9 billion by 2031—investors remain cautious about Novo’s ability to maintain market share and the overall efficacy of its drug pipeline.
The early adoption of Wegovy highlights a critical shift in obesity treatment accessibility, making it a potential game-changer in the sector. Market professionals should monitor how patient experiences evolve and whether Novo can capitalize on this momentum amid increasing competition.
Source: cnbc.com